Finding new ways to eliminate tuberculosis bacteria
Eradicating persistent M. tuberculosis by synthetic lethality of terminal respiratory oxidases
This study is looking at new ways to treat tuberculosis by finding out how certain drugs can work together to attack the bacteria, even when it's hiding and not causing symptoms, so that patients can have better chances of completely getting rid of the infection.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Albert Einstein College of Medicine NIH-funded |
| Lab location | 1 site (Bronx, United States) |
| Project ID | NIH-10509390 on NIH RePORTER |
What this research studies
This research focuses on developing new treatments for tuberculosis by targeting the bacteria's ability to survive in a dormant state. It investigates how certain drugs can work together to kill both active and inactive forms of the bacteria, particularly those that resist current antibiotics. The approach involves understanding the bacteria's energy production mechanisms and using new drug candidates that disrupt these processes. Patients may benefit from more effective therapies that can completely eradicate tuberculosis infections.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with tuberculosis, especially those with multidrug-resistant strains.
Not a fit: Patients who have not been diagnosed with tuberculosis or those with other unrelated infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments that completely eliminate tuberculosis infections, including drug-resistant strains.
How similar studies have performed: Previous research has shown promise in targeting bacterial energy production as a viable strategy for treating tuberculosis, indicating potential for success in this approach.
Where this research is happening
Bronx, United States
- Albert Einstein College of Medicine — Bronx, United States (Active)
Researchers
- Principal investigator: Berney, Michael — Albert Einstein College of Medicine
- Study coordinator: Berney, Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.